Development of cationic solid lipid nanoparticles with factorial design-based studies for topical administration of doxorubicin

Journal of Biomedical Nanotechnology

Volumn 8, Issue 2, 2012, Pages 219-228

  Taveira, Stephânia F ^a   De Campos Araújo, Luciana M P ^a   De Santana, Danielle C A S ^a   Nomizo, Auro ^a   De Freitas, Luiz Alexandre P ^a   Lopez, Renata F V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cationic solid lipid nanoparticles; Cellular uptake; Cytotoxicity; Doxorubicin; Factorial design; Melanoma

Indexed keywords

CELLULAR UPTAKE; DOXORUBICIN; FACTORIAL DESIGN; MELANOMA; SOLID LIPID NANOPARTICLE (SLN);

CELL CULTURE; CHEMOTHERAPY; CHLORINE COMPOUNDS; CYTOTOXICITY; DERMATOLOGY; DESIGN; ONCOLOGY; STEARIC ACID; SURFACE ACTIVE AGENTS; ZETA POTENTIAL;

NANOPARTICLES;

CATION; CETYLPYRIDINIUM SALT; DOXORUBICIN; GLYCEROL BEHENATE; NANOPARTICLE; POLOXAMER; SOLID LIPID NANOPARTICLE; STEARIC ACID; SURFACTANT;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG UPTAKE; FACTORIAL DESIGN; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SURFACE PROPERTY; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; ANALYSIS OF VARIANCE; ANIMALS; CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; FATTY ACIDS; MELANOMA, EXPERIMENTAL; MICE; NANOPARTICLES; PARTICLE SIZE; RESEARCH DESIGN; STEARIC ACIDS;

EID: 84861466359     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1383     Document Type: Article

References (34)

1. K. A. Janes, M. P. Fresneau, A. Marazuela, A. Fabra, and M. J. Alonso, Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 73, 255 (2001).
2. H. Herai, T. Gratieri, J. A. Thomazine, M. V. L. B. Bentley, and R. F. V. Lopez, Doxorubicin skin penetration from monoolein-containing propylene glycol formulation. Int. J. Pharm. 329, 88 (2007).
3. S. F. Taveira, A. Nomizo, and R. F. V. Lopez, Effect of the ion-tophoresis of chitosan gel on doxorubicin skin penetration and cyto-toxicity. J. Control. Release. 134, 35 (2009).
4. K. Tabatt, M. Samet, C. Olbrich, R. H. Muller, and C. Lehr, Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticles- mediated gene transfer. Eur. J. Pharm. Biopharm. 57, 155 (2004).
5. C. Olbrich, U. Bakowsky, C. Lehr, R. H. Muller, and C. Kneuer, Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release. 77, 345 (2001).
6. B. Baroli, Penetration of nanoparticles and nanomaterials in the skin: Fiction or reality? J. Pharm. Sci. 99, 21 (2010).
7. G. Cevc and U. Vieri, Nanotechnology and the transdermal route: A state of the arte review and critical appraisal. J. Control. Release 141, 277 (2010).
8. R. F. V. Lopez, J. E. Seto, D. Blankschtein, and R. Langer, Enhancing the trasndermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate. Biomaterials 32, 933941 (2011).
9. J. P. Ryman-Rasmussen, J. E. Riviere, and N. A. Monteiro-Riviere, Penetration of intact skin by quantum dots with diverse physico-chemical properties. Toxicol. Sci. 91, 159 (2006).
10. X. Wu, K. Landfester, A. Musyanovych, and R. H. Guy, Disposition of charged nanoparticles after their topical application to the skin. Skin. Pharmacol. Physiol. 23, 117 (2010).
11. E. Başaran, M. Demirel, B. Sirmagül, and Y. Yazan, Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsulation 27, 37 (2010).
12. S. Hoeller, A. Sperger, and C. Valenta, Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behavior and skin permeation. Int. J. Pharm. 370, 181 (2009).
13. R. H. Muller, M. Radtke, and S. A. Wissing, Solid lipid nanoparticles (SLN) and nanostructuctured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug. Deliv. Rev. 54, S131 (2002).
14. H. L. Wong, A. M. Rauth, R. Bendayan, and X. Y. Wu, In vivo evaluation of a new polymer-lipid hybrid nanoparticles (PLN) formulation of doxorubicin in a murine solid tumor model. Eur. J. Pharm. Biopharm. 65, 300 (2007).
15. S. Acharya and S. K. Sahoo, PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2010.10.008 (2010).
16. C. D. Tommaso, F. B.-Cohen, R. Gurny, and M. Moller, Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye. Ann Pharm. Fr. doi:10.1016/j.pharma.2011.01.001 (2011).
17. S. H. Choi, S.-E. Jin, M.-K. Lee, S.-J. Lim, J.-S. Park, B.-G. Kim, W. S. Ahn, and C.-K. Kim, Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 68, 545 (2008).
18. Y.-C. Kuo and H.-H. Chen, Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365, 206 (2009).
19. Y.-C. Kuo and C.-T. Liang, Cationic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells, Colloids Surf. B Biointerfaces doi:10.1016/j.colsurfb.2011.02.011 (2010).
20. Q. Lv, A. Yu, Y. Xi, H. Li, Z. Song, J. Cui, F. Cao, and G. Zhai, Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int. J. Pharm. 372, 191 (2009).
21. J. Fang, C. Fang, C. Liu, and Y. Su. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 70, 633 (2008).
22. F. Marquele-Oliveira, D. C. A. Santana, S. F. Taveira, D. M. Vermeulen, A. R. M. Oliveira, R. S. Silva, and R. F. V. Lopez, Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: Improvement in skin stability and in nitric oxide release by visible light irradiation. J. Pharm. Biomed. Anal. 53, 843 (2010).
23. S.-H. Hsu, C.-J. Wen, S. A. Al-Suwayeh, H.-W. Chang, T.-C. Yen, and J.-Y. Fang, Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: Apomorphine as a model drug. Nanotechnology 21, 1 (2010).
24. Q. Zhow and B. Chowbay, Determinantion of doxorubicin and its metabolites in rat serum and bile by LC: Application to preclinical pharmacokinetic studies. J. Pharm. Biomed. Anal. 30, 1063 (2002).
25. V. Teeranachaideekul, E. B. Souto, V. B. Junyaaprasert, and R. H. Muller, Cetylpalmitated-based NLC for topical delivery of coenzyme Q10 - development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm. 67, 141 (2007).
26. C. Yang, Z. L. Zhao, H. Y. Hu, K. X. Li, L. Sun, L. Li, and D. W. Chen, Preparation and optimization and characteristic of huperzine A loaded nanostructured lipid carriers. Chem. Pharm. Bull. 58, 656 (2010).
27. L. G. Souza, E. J. Silva, A. L. L. Martins, M. F. Mota, R. C. Braga, E. M. Lima, M. C. Valadares, S. F. Taveira, and R. N. Marreto, Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur. J. Pharm. Biopharm. doi:10.1016/j.ejpb.2011.02.012. (2011).
28. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55 (1983).
29. I. V. Zhigaltsev, G. Winters, M. Srinivasulu, J. Crawfor, M. Wong, L. Amankwa, D. Waterhouse, D. Masin, M. Webb, N. Harasym, L. Heller, M. B. Bally, M. A. Ciufolini, P. R. Cullis, and N. Maurer, Development of a weak-base docetaxel derivative that can be loade into lipid nanoparticles. J. Control. Release. 144, 332 (2010).
30. H. L. Wong, R. Bendayan, A. M. Rauth, and X. Y. Wu, Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release. 116, 275 (2006).
31. H. Yuan, J. Miao, Y.-Z. Du, J. You, F.-Q. Hu, and S. Zeng, Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348, 137 (2008).
32. H. Ali, A. B. Shirode, P. W. Sylvester, and S. Nazzal, Preparation, characterization and anticancer effects of simvastatin-Tocotrienol lipid nanoparticles. Int. J. Pharm. 389, 223 (2010).
33. H. L. Wong, R. Bendayan, A. M. Rauth, and X. Y. Wu, Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93, 1993 (2004).
34. W. Weyenber, P. Filev, D. V. Plas, J. Vandervoort, K. D. Smet, P. Sollie, and A. Ludwing, Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int. J. Pharm. 337, 291 (2007).